OpenEvidence, a leading medical search and AI platform for clinicians, has acquired Amaro, an AI-based advertising company founded by Kush and Sauren Khosla and backed by Google Ventures and Greycroft. Amaro specializes in utilizing intelligent automation to analyze and optimize end-to-end advertising deployment, enabling companies to streamline campaigns and enhance performance.
The acquisition is aimed at expanding OpenEvidence’s capabilities as it scales its platform for healthcare professionals. By integrating Amaro’s technology and team, OpenEvidence plans to build a modern, sustainable, and user-focused advertising infrastructure that supports its free-to-physician model. This approach enables verified U.S. clinicians to access high-quality medical information at no cost, supported by carefully managed advertising.
OpenEvidence currently powers more than 500,000 clinical conversations per day and is used by over 40 percent of U.S. physicians, many of whom rely on it for high-stakes decision-making at the point of care. The platform is adding approximately 90,000 clinicians each month, reflecting strong adoption across the medical community.
The deal follows OpenEvidence’s $210 million Series B funding round earlier this year, which valued the company at $3.5 billion. With Amaro’s expertise in fast, data-driven advertising optimization, OpenEvidence aims to enhance its monetization strategy while maintaining its commitment to delivering trusted, evidence-based information to clinicians nationwide.
KEY QUOTES:
“I’ve had the privilege of backing both OpenEvidence and Amaro, and it’s exciting to see them join forces. The Khosla brothers have built an exceptional team at Amaro — combining resilience, vision, and technical excellence. This acquisition is a great fit, as Amaro’s team and technology will help OpenEvidence accelerate its growth and further expand access to a trusted tool for clinicians.”
Sangeen Zeb, general partner at GV
“OpenEvidence powers over half a million clinical conversations per day to verified American clinicians–for free. We believe every patient deserves to be seen by physicians with access to the highest quality information in the world, and our free-to-physician, ad-supported model enables every single practice in the country to leverage this technology, no matter the level of resources available to them. The Amaro team moves fast, ships relentlessly, and shares our obsession with quality. This acquisition gives us a huge boost as we scale, and Amaro is a natural fit that accelerates our vision.”
Zachary Ziegler, cofounder of OpenEvidence
